NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2-YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL

https://storage.unitedwebnetwork.com/files/1099/0eec9b8780e5e8f258f4fb65d9aaf1b9.pdf

Jens Kristensen jens.kristensen@calliditas.com Calliditas Therapeutics AB N/A Stockholm

Andrew Stone andrew@stonebiostatistics.com Stone Biostatistics Ltd. N/A Crewe

Jürgen Floege jfloege@ukaachen.de Rheinisch Westfälische Technische Hochschule Aachen University Hospital Department of Nephrology and Clinical Immunology Aachen

Vladimír Tesař Vladimir.Tesar@vfn.cz First Faculty of Medicine and General University Hospital, Charles University Department of Nephrology Prague

Hernán Trimarchi htrimarchi@hotmail.com Hospital Británico de Buenos Aires Nephrology Service Buenos Aires

Hong Zhang hongzh@bjmu.edu.cn Peking University First Hospital, Peking University Institute of Nephrology Renal Division Beijing

Necmi Eren necmieren.kou@gmail.com Kocaeli University Department of Nephrology Kocaeli

Alexander Paliege alexander.paliege@uniklinikum-dresden.de University Hospital Carl Gustav Carus, Technische Universität Dresden Division of Nephrology, Department of Internal Medicine III Dresden

Heather N. Reich Heather.Reich@uhn.ca University of Toronto Department of Medicine Toronto, ON

Brad H. Rovin Brad.Rovin@osumc.edu The Ohio State University Wexner Medical Center Division of Nephrology Columbus, OH

Richard Lafayette czar@stanford.edu Stanford University Division of Nephrology, Department of Medicine Stanford, CA